Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

169 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass.
Shernan SK, Fitch JC, Nussmeier NA, Chen JC, Rollins SA, Mojcik CF, Malloy KJ, Todaro TG, Filloon T, Boyce SW, Gangahar DM, Goldberg M, Saidman LJ, Mangano DT; Pexelizumab Study Investigators. Shernan SK, et al. Ann Thorac Surg. 2004 Mar;77(3):942-9; discussion 949-50. doi: 10.1016/j.athoracsur.2003.08.054. Ann Thorac Surg. 2004. PMID: 14992903 Clinical Trial.
Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: a randomized trial.
Verrier ED, Shernan SK, Taylor KM, Van de Werf F, Newman MF, Chen JC, Carrier M, Haverich A, Malloy KJ, Adams PX, Todaro TG, Mojcik CF, Rollins SA, Levy JH; PRIMO-CABG Investigators. Verrier ED, et al. Among authors: shernan sk. JAMA. 2004 May 19;291(19):2319-27. doi: 10.1001/jama.291.19.2319. JAMA. 2004. PMID: 15150203 Clinical Trial.
Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery.
Carrier M, Ménasché P, Levy JH, Newman MF, Taylor KM, Haverich A, Chen JC, Shernan SK, Van de Werf F, van der Laan M, Todaro TG, Adams PX, Verrier ED. Carrier M, et al. Among authors: shernan sk. J Thorac Cardiovasc Surg. 2006 Feb;131(2):352-6. doi: 10.1016/j.jtcvs.2005.10.011. J Thorac Cardiovasc Surg. 2006. PMID: 16434264 Free article. Clinical Trial.
Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials.
Smith PK, Shernan SK, Chen JC, Carrier M, Verrier ED, Adams PX, Todaro TG, Muhlbaier LH, Levy JH; PRIMO-CABG II Investigators. Smith PK, et al. Among authors: shernan sk. J Thorac Cardiovasc Surg. 2011 Jul;142(1):89-98. doi: 10.1016/j.jtcvs.2010.08.035. Epub 2010 Sep 28. J Thorac Cardiovasc Surg. 2011. PMID: 20880552 Free article. Clinical Trial.
169 results